89bio, Inc. Quarterly Operating Income (Loss) in USD from Q2 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
89bio, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2018 to Q3 2024.
  • 89bio, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$152M, a 286% decline year-over-year.
  • 89bio, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$304M, a 124% decline year-over-year.
  • 89bio, Inc. annual Operating Income (Loss) for 2023 was -$151M, a 47.9% decline from 2022.
  • 89bio, Inc. annual Operating Income (Loss) for 2022 was -$102M, a 13.9% decline from 2021.
  • 89bio, Inc. annual Operating Income (Loss) for 2021 was -$89.7M, a 81.8% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$304M -$152M -$113M -286% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$191M -$53.4M -$11.3M -26.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-05
Q1 2024 -$180M -$57.3M -$28.8M -101% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$151M -$41.2M -$15.8M -62.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-01
Q3 2023 -$135M -$39.3M -$12.3M -45.5% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$123M -$42.1M -$17.4M -70.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-05
Q1 2023 -$106M -$28.5M -$3.42M -13.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$102M -$25.4M +$879K +3.35% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-01
Q3 2022 -$103M -$27M +$1.17M +4.15% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$104M -$24.7M -$4.19M -20.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 -$100M -$25.1M -$10.4M -70.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 -$89.7M -$26.2M -$13.7M -109% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-01
Q3 2021 -$76M -$28.2M -$13.8M -95.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$62.3M -$20.6M -$8.88M -76.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$53.4M -$14.7M -$4.04M -37.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$49.4M -$12.5M -$2.94M -30.5% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-24
Q3 2020 -$46.4M -$14.4M -$22.6M -276% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$23.8M -$11.7M -$15.7M -392% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-13
Q1 2020 -$8.12M -$10.7M -$5.87M -121% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-14
Q4 2019 -$2.25M -$9.61M -$5.2M -118% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-18
Q3 2019 $2.96M $8.2M +$12M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-13
Q2 2019 -$9.03M $4M +$11M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13
Q1 2019 -$20M -$4.83M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-13
Q4 2018 -$4.41M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-18
Q3 2018 -$3.79M Jul 1, 2018 Sep 30, 2018 10-K 2020-03-18
Q2 2018 -$6.97M Apr 1, 2018 Jun 30, 2018 10-K 2020-03-18
* An asterisk sign (*) next to the value indicates that the value is likely invalid.